TGFBR1 haplotypes and risk of non-small-cell lung cancer.

Transforming growth factor beta (TGF-beta) receptors are centrally involved in TGF-beta-mediated cell growth and differentiation and are frequently inactivated in non-small-cell lung cancer (NSCLC). Constitutively decreased type I TGF-beta receptor (TGFBR1) expression is emerging as a novel tumor-predisposing phenotype. The association of TGFBR1 haplotypes with risk for NSCLC has not yet been studied. We tested the hypothesis that single-nucleotide polymorphisms (SNP) and/or TGFBR1 haplotypes are associated with risk of NSCLC. We genotyped six TGFBR1 haplotype-tagging SNPs (htSNP) by PCR-RFLP assays and one htSNP by PCR-single-strand conformation polymorphism assay in two case-control studies. Case-control study 1 included 102 NSCLC patients and 104 healthy controls from Suzhou. Case-control study 2 included 131 patients with NSCLC and 133 healthy controls from Wuxi. Individuals included in both case-control studies were Han Chinese. Haplotypes were reconstructed according to the genotyping data and linkage disequilibrium status of these seven htSNPs. None of the htSNP was associated with NSCLC risk in either study. However, a four-marker CTGC haplotype was significantly more common among controls than among cases in both studies (P = 0.014 and P = 0.010, respectively), indicating that this haplotype is associated with decreased NSCLC risk {adjusted odds ratio [OR], 0.09 [95% confidence interval (95% CI), 0.01-0.61] and 0.11 [95% CI, 0.02-0.59], respectively}. Combined analysis of both studies shows a strong association of this four-marker haplotype with decreased NSCLC risk (adjusted OR, 0.11; 95% CI, 0.03-0.39). This is the first evidence of an association between a TGFBR1 haplotype and risk for NSCLC.

[1]  J. Graff,et al.  Transforming Growth Factor-β Receptor Type I Gene Is Frequently Mutated in Ovarian Carcinomas , 2001 .

[2]  Simon Heath,et al.  Lung cancer susceptibility locus at 5p15.33 , 2008, Nature Genetics.

[3]  J. Deddens,et al.  An intronic variant of the TGFBR1 gene is associated with carcinomas of the kidney and bladder , 2004, International journal of cancer.

[4]  F. Sofi,et al.  ACE and TGFBR1 genes interact in influencing the susceptibility to abdominal aortic aneurysm. , 2009, Atherosclerosis.

[5]  D. Eccles,et al.  Transforming Growth Factor (cid:1) Receptor 1 Polyalanine Polymorphism and Exon 5 Mutation Analysis in Breast and Ovarian Cancer , 2022 .

[6]  F. Bray,et al.  Estimation and projection of the national profile of cancer mortality in China: 1991–2005 , 2004, British Journal of Cancer.

[7]  S. Liyanarachchi,et al.  Germline Allele-Specific Expression of TGFBR1 Confers an Increased Risk of Colorectal Cancer , 2008, Science.

[8]  G. von Heijne,et al.  Somatic acquisition and signaling of TGFBR1*6A in cancer. , 2005, JAMA.

[9]  H. Hollema,et al.  Structural alterations of transforming growth factor‐β receptor genes in human cervical carcinoma , 1999, International journal of cancer.

[10]  J. Deddens,et al.  Int7G24A Variant of Transforming Growth Factor-β Receptor Type I Is Associated with Invasive Breast Cancer , 2006, Clinical Cancer Research.

[11]  Zeyi Liu,et al.  No Association between TGFBR1*6A and Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  H. Ostrer,et al.  TβR-I(6A) Is a Candidate Tumor Susceptibility Allele , 1999 .

[13]  Yong-yong Shi,et al.  SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci , 2023, Cell Research.

[14]  C. Carlson,et al.  Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. , 2004, American journal of human genetics.

[15]  F. Aiello,et al.  Gene expression of transforming growth factor beta receptors I and II in non-small-cell lung tumors. , 2003, Cytokine.

[16]  Hong-Tao Zhang.  Int7G24A variant of the TGFBR1 gene and cancer risk: a meta-analysis of three case-control studies. , 2005, Lung cancer.

[17]  T. Wheeler,et al.  Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  H. Ahn,et al.  Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  P. Shields.  Molecular epidemiology of smoking and lung cancer , 2002, Oncogene.

[20]  M. Abe,et al.  Cytokine , 2020, Bone Marrow Transplantation.

[21]  S. Thorgeirsson,et al.  Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis. , 2001, Cancer research.

[22]  M. Xiong,et al.  Haplotypes vs single marker linkage disequilibrium tests: what do we gain? , 2001, European Journal of Human Genetics.

[23]  H. Friess,et al.  Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. , 1999, Pancreas.

[24]  H. Lodish,et al.  A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma , 1996, Molecular and cellular biology.

[25]  M. Reiss,et al.  Novel inactivating mutations of transforming growth factor‐β type I receptor gene in head‐and‐neck cancer metastases , 2001, International journal of cancer.

[26]  A. Rademaker,et al.  TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Chiang-Ching Huang,et al.  TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through RhoA activation. , 2008, Cancer research.

[28]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[29]  S. Picelli,et al.  TGFBR1*6A and Int7G24A variants of transforming growth factor-β receptor 1 in Swedish familial and sporadic breast cancer , 2007, British Journal of Cancer.

[30]  J. Massagué,et al.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus. , 2003, Cell.

[31]  Keunchil Park,et al.  Effects of transforming growth factor (TGF-) receptor on lung carcinogenesis , 2002 .

[32]  J. Curtis,et al.  The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. , 2008, Lung cancer.

[33]  L. Wakefield,et al.  Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency , 1998, Nature Medicine.

[34]  Chiang-Ching Huang,et al.  Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development. , 2009, Cancer research.

[35]  N. Wake,et al.  Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer. , 2000, Cancer research.

[36]  Q. Qi,et al.  Mutational analysis of the transforming growth factor beta receptor type I gene in primary non-small cell lung cancer. , 2003, Lung cancer.

[37]  Paolo Vineis,et al.  International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. , 2008, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.